Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 6/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 13/20 | 0.46 |
| ▸ | MMP9 | P14780 | 10/20 | 0.46 |
| ▸ | MMP1 | P03956 | 9/20 | 0.46 |
| ▸ | MMP3 | P08254 | 9/20 | 0.46 |
| ▸ | MMP7 | P09237 | 9/20 | 0.46 |
| ▸ | MMP13 | P45452 | 9/20 | 0.46 |
| ▸ | MMP14 | P50281 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764111 | 1.00 | ADAMTS5 (0.78) | ADAMTS5MAPK1CYP2C19MMP2MMP9 | |
| SCHEMBL5492288 | 1.00 | ADAMTS5 (0.78) | ADAMTS5MAPK1CYP2C19MMP2MMP9 | |
| SCHEMBL2764182 | 0.92 | ADAMTS5 (0.86) | ADAMTS5MAPK1CYP2C19MMP2MMP9 | |
| SCHEMBL2764179 | 0.92 | ADAMTS5 (0.86) | ADAMTS5MAPK1CYP2C19MMP2MMP9 | |
| SCHEMBL6058646 | 0.88 | ADAMTS5 (1.00) | ADAMTS5MAPK1CYP2C19MMP2 | |
| SCHEMBL2764374 | 0.88 | ADAMTS5 (1.00) | ADAMTS5MAPK1CYP2C19MMP2 | |
| SCHEMBL2764561 | 0.88 | ADAMTS5 (1.00) | ADAMTS5MAPK1CYP2C19MMP2 | |
| SCHEMBL13398332 | 0.88 | ADAMTS5 (1.00) | ADAMTS5MAPK1CYP2C19MMP2 | |
| SCHEMBL2765163 | 0.88 | ADAMTS5 (1.00) | ADAMTS5MAPK1CYP2C19MMP2 | |
| SCHEMBL2764668 | 0.88 | ADAMTS5 (1.00) | ADAMTS5MAPK1CYP2C19MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694410-B1 | CYCLOPROPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2010-04-14 | — | — | EP | claimed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | claimed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | claimed |
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-07 | — | — | US | claimed |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2010-04-29 | — | — | US | disclosed |
| EP-1694410-B1 | CYCLOPROPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | disclosed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1694410-A2 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058884-A2 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | ADAMTS5 38/4885MAPK1 2135/4885CYP2C19 158/4885 |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MMP13, MMP9, MMP11 | ADAMTS5 38/4885MAPK1 2090/4885CYP2C19 159/4885 |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | ADAMTS5 38/4885MAPK1 2090/4885CYP2C19 159/4885 |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | ADAMTS5 38/4885MAPK1 2078/4885CYP2C19 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.